GalNAc3-conjugated 2′-MOE antisense oligonucleotide targeting apolipoprotein(a) mRNA for lipoprotein(a) reduction
A hepatocyte-directed, triantennary N-acetylgalactosamine-conjugated antisense oligonucleotide developed by Ionis Pharmaceuticals and licensed to Novartis, designed to selectively reduce circulating lipoprotein(a) concentrations by RNase H1-mediated degradation of apolipoprotein(a) mRNA in hepatocytes, currently under evaluation in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial.
Abstract
Pelacarsen (ISIS 681257; also designated IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230) is a second-generation, hepatocyte-directed antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) ligand, designed to reduce circulating lipoprotein(a) [Lp(a)] concentrations by selective inhibition of apolipoprotein(a) [apo(a)] synthesis in the liver. The compound targets the messenger RNA transcribed from the LPA gene, binding with high specificity and triggering RNase H1-mediated cleavage and subsequent degradation of the transcript, thereby preventing translation of the apo(a) protein that is the defining structural component of the Lp(a) particle.
Lipoprotein(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis (CAVS), and thrombotic events. Plasma Lp(a) concentrations are primarily determined by LPA gene variation and are minimally responsive to lifestyle modification or conventional lipid-lowering pharmacotherapy including statins, ezetimibe, and PCSK9 inhibitors. Approximately 20 to 25 percent of the global population carries Lp(a) concentrations above 50 mg/dL, the threshold at which epidemiological and Mendelian randomization data consistently demonstrate elevated cardiovascular risk. Prior to the development of targeted Lp(a)-lowering agents, no pharmacotherapy had demonstrated selective, potent, and sustained reduction of Lp(a) in a manner suitable for chronic cardiovascular risk management.
The compound was well tolerated; the principal adverse events were mild injection site reactions.
Enrollment was completed in 2022; topline results are anticipated in 2026. A companion Phase 3 trial (Lp(a)FRONTIERS CAVS) evaluates pelacarsen in calcific aortic valve stenosis progression. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.